Drug Trial Radar · NCT07140809
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Sep 9, 2025
Primary completion
Jul 31, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia
Conditions
- Hypertriglyceridemia
Interventions
JMT202 injectionBiological
Subcutaneous injection
PlaceboOther
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of TEAETime frame: Day 1 to 99
- Number of participants with vital sign abnormalitiesTime frame: Day 1 to 99
- Number of participants with physical examination abnormalitiesTime frame: Day 1 to 99
- Number of participants with laboratory tests abnormalitiesTime frame: Day 1 to 99
- Number of participants with 12-lead electrocardiogram abnormalitiesTime frame: Day 1 to 99
- Number of participants with injection site reactions abnormalitiesTime frame: Day 1 to 63
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Peking University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.